Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Guo, Yongjing ^a   Hill, Andrew A ^a   Ramsey, Renee C ^a   Immermann, Frederick W ^a   Corcoran, Christopher ^a   Young, Deborah ^a   LaVallie, Edward R ^a   Ryan, Mark ^a   Bechard, Theresa ^a   Pfeifer, Richard ^b   Warner, Garvin ^a   Bologna, Marcia ^a   Bloom, Laird ^a   O'Toole, Margot ^a,c  

^a PFIZER INC   (United States)

^b SHIRE   (United States)

^c Inflammation and Immunology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AB 01 ANTIBODY; CYTOKINE; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 21 RECEPTOR ANTIBODY; LIGAND; MONOCLONAL ANTIBODY CD28; PROTEIN ANTIBODY; RECOMBINANT INTERLEUKIN 21; RNA; TGN 1412; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CROSS LINKING; DRUG BINDING; FLUORESCENCE ACTIVATED CELL SORTING; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE ADHERENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MONKEY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RNA ISOLATION; SIGNAL TRANSDUCTION;

EID: 77952624506     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-50     Document Type: Article

References (27)

1. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, Godfrey DI. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007, 178:2827-2834.
2. Ettinger R, Kuchen S, Lipsky PE. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 2008, 223:60-86. 10.1111/j.1600-065X.2008.00631.x, 18613830.
3. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63. 10.1038/35040504, 11081504.
4. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008, 20:295-301. 10.1016/j.coi.2008.02.004, 2546604, 18554883.
5. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487. 10.1038/nature05970, 17581588.
6. Fina D, Sarra M, Caruso R, Del Vecchio Blanco G, Pallone F, MacDonald TT, Monteleone G. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 2008, 57:887-892. 10.1136/gut.2007.129882, 17965065.
7. Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, Stolfi C, Cardolini I, Dottori M, Boirivant M, Pallone F, Macdonald TT, Monteleone G. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008, 134:1038-1048. 10.1053/j.gastro.2008.01.041, 18395085.
8. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007, 178:3822-3830.
9. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, Brown TP, Nickerson-Nutter C, Keith JC, Collins M. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007, 56:1152-1163. 10.1002/art.22452, 17393408.
10. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci USA 2008, 105:14028-14033. 10.1073/pnas.0804358105, 2544573, 18779574.
11. Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis 2008, 67(Suppl 3):iii83-86. 10.1136/ard.2008.098400, 19022821.
12. Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, Spaulding V, Bennett F, Lowe L, Andreyeva T, Lowe D, Lane S, Thom G, Valge-Archer V, Gill D, Young D, Bloom L. In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. MAbs 2010,
13. Vugmeyster Y, Allen S, Szklut P, Bree A, Ryan M, Ma M, Spaulding V, Young D, Guay H, Bloom L, Leach MW, O'Toole M, Adkins K. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys. J Transl Med 2010, 8:41. 10.1186/1479-5876-8-41, 2880981, 20420683.
14. Stebbings R, Findlay L, Edwards C, Eastwood D, Bird C, North D, Mistry Y, Dilger P, Liefooghe E, Cludts I, Fox B, Tarrant G, Robinson J, Meager T, Dolman C, Thorpe SJ, Bristow A, Wadhwa M, Thorpe R, Poole S. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007, 179:3325-3331.
15. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355:1018-1028. 10.1056/NEJMoa063842, 16908486.
16. Expert Scientific Group on Phase I Clinical Trials, Final Report. 2006,
17. Goodyear M. Learning from the TGN1412 trial. Bmj 2006, 332:677-678. 10.1136/bmj.38797.635012.47, 1410845, 16554332.
18. Mehrishi JN, Szabo M, Bakacs T. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials. Vaccine 2007, 25:3517-3523. 10.1016/j.vaccine.2007.02.078, 17397974.
19. Nada A, Somberg J. First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. Am J Ther 2007, 14:594-604. 10.1097/MJT.0b013e31813737dd, 18090886.
20. Black R, Ekman L, Lieberburg I, Grundman M, Callaway J, Gregg KM, Jacobsen JS, Gill D, Tchistiakova L, Windom A. Immunotherapy regimes dependent on APOE status, patent application number 2009015. 2009, , http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22Black,+Ronald%22.IN.&OS=IN/%22Black,+Ronald%22&RS=IN/%22Black,+Ronald%22
21. Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N, Cook TA, Lee J, Widom A, Agostinelli R, Bree A, Schlerman FJ, Olland S, Wadanoli M, Sypek J, Gill D, Goldman SJ, Tchistiakova L. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008, 325:882-892. 10.1124/jpet.108.136515, 18337474.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 1995, 289.
24. Agarwal A, Salem P, Robbins KC. Involvement of p72syk, a protein-tyrosine kinase, in Fc gamma receptor signaling. J Biol Chem 1993, 268:15900-15905.
25. Ghazizadeh S, Bolen JB, Fleit HB. Physical and functional association of Src-related protein tyrosine kinases with Fc gamma RII in monocytic THP-1 cells. J Biol Chem 1994, 269:8878-8884.
26. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290. 10.1146/annurev.immunol.19.1.275, 11244038.
27. Salcedo TW, Kurosaki T, Kanakaraj P, Ravetch JV, Perussia B. Physical and functional association of p56lck with Fc gamma RIIIA (CD16) in natural killer cells. J Exp Med 1993, 177:1475-1480. 10.1084/jem.177.5.1475, 2191009, 8478617.